http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2700679-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_850a17186ff51f03c607cf42a534a635 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-72 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4166 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-72 |
| filingDate | 2003-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c93726f0b46de1baead06336b158dac http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c3f777621e1340a55f18038e7470554b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aae1966c0d3441a264e12ec86eb22357 |
| publicationDate | 2003-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2700679-A1 |
| titleOfInvention | Novel crystal form of 5-hydroxy-1-methylhydantoin |
| abstract | The present invention is directed to a process for producing 5-hydroxy-1-methylimidazolidin-2,4-dione by hydrolyzing a brominated product of 1-methylhydantoin. The 5-hydroxy-1-methylimidazolidin-2,4-dione is used in the preparation of novel II-form crystals of 5-hydroxy-1-methylhydantoin. Conventional I-form crystals of 5-hydroxy-1-methylhydantoin contain, remaining therein in a considerable amount, the organic solvent used in a purification step. In contrast, in II-form crystals, the amount of the organic solvent remaining therein is smaller than the detection limit. Namely, the II-form crystals contain substantially no residual organic solvent. The novel II-form crystals of 5-hydroxy-1-methylhydantoin obtained through recrystallization from water not only contain substantially no residual organic solvent, but also have a high bulk density and are hence advantageous for pharmaceutical preparation. They further have properties advantageous for production, such as low adhesion. The crystals are significantly useful as a material for medicines required to have high safety, such as drugs for renal insufficiency. |
| priorityDate | 2002-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 33.